Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Status:
Recruiting
Trial end date:
2022-04-03
Target enrollment:
Participant gender:
Summary
The primary objectives of this phase 3, multicenter, randomized, double-blind,
placebo-controlled study are to determine the efficacy, and safety/tolerability, of
molnupiravir (MK-4482) in adults who reside with a person infected with COVID-19. It is
hypothesized that molnupiravir is superior to placebo in preventing laboratory-confirmed
COVID-19 infection through Day 14 in participants (regardless of baseline viral test result)
who do not have confirmed or suspected COVID-19 at time of screening and randomization.